Earnings call transcript: Aurubis Q2 2025/2026 misses expectations, stock falls
Earnings call transcript: Aurubis Q2 2025/2026 misses expectations, stock falls
Earnings call transcript: Aurubis Q2 2025/2026 misses expectations, stock falls
Latest in Markets
-
HSBC to redeem CNH2.75 billion notes due 2027 on June 29
-
Goldman Sachs upgrades ORIC Pharmaceuticals stock rating to buy
-
BofA raises Legence stock price target to $105 on strong Q1 results
-
Evercore ISI initiates Devon Energy stock with In Line rating
-
Exclusive-Schroders to exit wholly-owned China fund management unit, sources say
-
America’s most powerful CEOs don’t have much to show from their China trip so far
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.